Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8696410 | 0.67 | ATAD2 (0.38) | BRD4CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL11869254 | 0.65 | BRPF1 (0.35) | BRD4CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL3806347 | 0.65 | FEN1 (0.38) | BRD4CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL24665501 | 0.62 | ALDH1A1 (0.39) | BRD4CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL15125556 | 0.62 | DRD2 (0.43) | CYP1A2POLBCYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL2714078 | 0.62 | FEN1 (0.39) | ALDH1A1 | |
| SCHEMBL14491564 | 0.60 | BRD4 (0.36) | BRD4CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL19235507 | 0.60 | BRD4 (0.36) | BRD4POLBALDH1A1 | |
| SCHEMBL18937487 | 0.59 | BRD4 (0.35) | BRD4POLBALDH1A1 | |
| SCHEMBL23029099 | 0.59 | BRD4 (0.35) | BRD4POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023152568-A2 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LUNG CANCER | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2023-08-17 | — | — | WO | disclosed |
| EP-4226158-A1 | METHODS OF DIAGNOSING TUBERCULOSIS AND DIFFERENTIATING BETWEEN ACTIVE AND LATENT TUBERCULOSIS | Cepheid (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-2591363-A2 | DIAGNOSIS AND TREATMENT OF BREAST CANCER | The Regents Of The University Of Michigan (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2451983-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACULAR DEGENERATION | The Regents of the University of Michigan (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012006421-A2 | DIAGNOSIS AND TREATMENT OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011006161-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2171094-A2 | MIPOL1-ETV1 GENE REARRANGEMENTS | The Regents of the University of Michigan (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2115162-A2 | ADRB2 CANCER MARKERS | The Regents of the University of Michigan (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009076629-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009009431-A2 | MIPOL1-ETV1 GENE REARRANGEMENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009006577-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008089397-A2 | ADRB2 CANCER MARKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1112377-A4 | NUCLEIC ACID-COUPLED COLORIMETRIC ANALYTE DETECTORS | UNIV CALIFORNIA (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1112377-A1 | NUCLEIC ACID-COUPLED COLORIMETRIC ANALYTE DETECTORS | The Regents of the University of California (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-1999067423-A1 | NUCLEIC ACID-COUPLED COLORIMETRIC ANALYTE DETECTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-12-29 | — | — | WO | disclosed |